MorphoSys, a German-based antibody library technology company, and Immatics Biotechnologies, a German-based clinical-stage biopharmaceutical company, have formed a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells.
The collaboration agreement provides MorphoSys with access to several proprietary tumor-associated peptides (TUMAPs) discovered using Immatics’ XPRESIDENT platform to develop novel antibody-based therapeutics against those targets in a number of solid and hematological cancers. XPRESIDENT enables access to novel antibody targets associated with proteins that are present inside cancer cells. In return, Immatics will be provided with MorphoSys’ Ylanthia antibodies against a number of its TUMAPs, with proprietary development rights.
The companies will pay each other milestones based on their respective development progress and royalties on marketed products. Financial details of the agreement have not been disclosed.